Lactobacillus reuteriLactobacillus reuteri
probiotic_strain
别名: L. reuteri, Limosilactobacillus reuteri, DSM 17938, ATCC 55730, BioGaia
About
Lactobacillus reuteri is one of the few probiotic species that naturally colonizes the human GI tract from infancy. It produces reuterin, a broad-spectrum antimicrobial compound, and research suggests it may help support gastric motility and reduce visceral discomfort through TRPV1 channel modulation. The DSM 17938 strain has been extensively studied for supporting comfort in colicky infants.
How It Works
Produces reuterin, a broad-spectrum antimicrobial compound (3-hydroxypropionaldehyde); accelerates gastric emptying via enteric nervous system modulation; reduces visceral pain through TRPV1 channel modulation; modulates gut motility and colonic transit.
Evidence For Conditions
| 健康状况 | 等级 | 研究数量 | 受试者 | |
|---|---|---|---|---|
| Bloating and Intestinal Gas | B | 7 | 500 | 查看 → |
| Gastroesophageal Reflux Disease (GERD) | C | 2 | 250 | 查看 → |
Side Effects
- Mild gas in initial days of use
- Occasional increased fussiness in infants during adjustment (transient)
- Rare loose stools
- Very rare: bacteremia in immunocompromised individuals
Drug & Supplement Interactions
- Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
- Immunosuppressants (theoretical risk in immunocompromised patients)
- Proton pump inhibitors (altered gastric pH may affect colonization)
请务必告知您的医疗保健提供者您正在服用的所有补充剂。
Related Ingredients
FDA 免责声明: 这些声明未经美国食品药品监督管理局(FDA)评估。本网站上的产品和信息无意用于诊断、治疗、治愈或预防任何疾病。所展示的证据等级基于我们对已发表的同行评审研究的分析,不构成医疗建议。在开始任何补充剂方案之前,请务必咨询您的医疗保健提供者。